ELISA revealed that the levels of tissue plasminogen activator, plasminogen activator inhibitor 1, crosslaps, and anti-p53 antibody in patients with ONFH were always significantly different among patients with OA, RA, and fracture. This evidence concerns the gene TP53 and rheumatoid arthritis.